• Publications
• Experience
• About

Professional Focus

Dr. Roach is recognized as a major authority on the treatment of clinically localized prostate cancer. He served as lead author for the 1996, 2000 and pending 2006 editions of the American College of Radiology Appropriateness Criteria Guidelines for defining how men in this country should be simulated and treated with radiotherapy. He also served on the NCI Intensity Modulated Radiotherapy Working Group to define jargon and criteria for defining the use of this new technology. He helped co-author the 2001 prostate cancer screening guidelines put forth by the American Cancer Society. He is best known for the recently completed prospective randomized RTOG trial that demonstrated the value of pelvic nodal radiotherapy for patients with high risk prostate cancer.

Education

Professional Experience

Awards & Honors

Recent Significant Publications

Kaidar-Person O, Roach M 3rd, Créhange G. Whole-Pelvic Nodal Radiation Therapy in the Context of Hypofractionation for High-Risk Prostate Cancer Patients: A Step Forward. Int J Radiat Oncol Biol Phys. 2013 Mar 19.

Chang AJ, Roach M 3rd. Cautious Optimism for Extreme Dose Escalation in Prostate Cancer. Eur Urol. 2013 Feb 28.

Cury FL, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C.Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Mar 15.

Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC.Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes.Int J Radiat Oncol Biol Phys. 2013 Mar 5.

Roach M 3rd, Thomas K.Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012 Dec;2012(45):221-9.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M 3rd.Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012 Dec;38(8):956-67.

Roach M 3rd. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012 Jul;110(2):225.

Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M 3rd. Management of prostate cancer patients with lymph node involvement: A rapidly evolving paradigm. Cancer Treat Rev. 2012 Jun 13.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd. Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrent After Initial PPI for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 4.

Chang AJ, Roach M 3rd. Radium-223: down to the bone, and less is more. Oncology (Williston Park). 2012 Apr;26(4):342, 344. 

Michalski J, Winter K, Roach M, Markoe A, Sandler HM, Ryu J, Parliament M, Purdy JA, Valicenti RK, Cox JD. Clinical Outcome of Patients Treated With 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e363-70.

Meijer HJ, Debats OA, Roach M 3rd, Span PN, Witjes JA, Kaanders JH, van Lin EN, Barentsz JO. Magnetic Resonance Lymphography Findings in Patients With Biochemical Recurrent After Prostatectomy and the Relation With the Stephenson Nomogram. Int J Radiat Oncol Biol Phys. 2012 Apr 18.

Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, Montorsi F, Roach M 3rd, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ. High-risk Prostate Cancer: from Definition to Contemporary Management, Eur Urol. 2012 Jun;61(6):1096-106.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x.

Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M 3rd, Jung AJ, Carroll PR, Coakley FV. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI study. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e787-93. Epub 2012 Feb 11.

Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M 3rd, Cheung P, Sahgal A. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e657-62.

Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34.

Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K, Hsu IC. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):222-7.

Roach M 3rd. Editorial comment. Urology. 2011 Dec;78(6):1367-8. 

Moul JW, Evans CP, Gomella LG, Roach M 3rd, Dreicer R. Traditional approches to androgen deprivation therapy. Urology. 2011 Nov;78(5 Suppl):S485-93.

Moul JW, Kibel AS, Roach M 3rd, Dreicer R. Indications and practice with androgen deprivation therapy. Urology. 2011 Nov;78(5 Suppl):S478-81.

Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M 3rd, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body rediotherapy. Phys Med Biol. 2011 Dec 21;56(24):7767-75. Epub 2011 Nov 22.

Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M 3rd, van Poppel H, Zietman A. Postoperative radiation therapy for pathological advanced prostate cancer after radical prostatectomy. Eur Urol. 2012 Mar;61(3):443-51.

Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M 3rd, Hsu IC. Urethra low-dose tunnels: Validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy. 2011 Sep 20.

Moyad MA, Roach M 3rd. Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment. Urol Clin North Am. 2011 Aug;38(3):303-12.

Chen CP, Staggers FE, Roach M 3rd. Benefits and pitfalls of prostate cancer screening: "no proof of benefit" does not equal "proof of no benefit". Oncology (Williston Park). 2011 May;25(6):466, 468. No abstract available.

Kumbhani SR, Coakley FV, McCulloch CE, Wang ZJ, Kurhanewicz J, Roach M 3rd, Westphalen AC. Endorectal MRI after radiation therapy: questioning the sextant analysis. J Magn Reson Imaging. 2011 May;33(5):1086-90. doi: 10.1002/jmri.22561.

Morikawa LK, Roach M 3rd. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rational, and future directions. Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):6-16.

Roach M 3rd, Alberini JL, Pecking AP, Testori A, Verrecchia F, Soteldo J, Ganswindt U, Joyal JL, Babich JW, Witte RS, Unger E, Gottlieb R. Diagnostic and therapeutic imaging dor cancer: therapeutic considerations and future directions. J Surg Oncol. 2011 May 1;103(6):587-601.

Roach M 3rd. Editorial comment. Urology. 2011 Apr;77(4):991-2; author reply 992-3. No abstract available.

Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1293-301. Epub 2011 Mar 31. Review.

Hayes M, Roach M 3rd. Predicting the risk of pelvic node involvement in men with prostate cancer in the contemporary era: change you can beleive?: in regard to Yu, et al. (Int J Radiat Oncol Bio Phys in press). Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1598; author reply 1598-9. No abstract available.

Dasgupta T, Barani IJ, Roach M 3rd. Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patient. Radiat Oncol. 2011 Feb 14;6:16.

Roach M. Editorial comment. BJU Int. 2011 Jan;107(2):232-3.

Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34.

Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K, Hsu IC. High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):222-7.

Xia P, Qi P, Hwang A, Kinsey E, Pouliot J, Roach M 3rd. Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes. Med Phys. 2010 Sep;37(9):5006-13.

Roach M 3rd. Primary focal unilateral nerve-sparing cryoablation for very early prostate cancer: is it enough or too much, or do we know? Cancer J. 2010 Sep-Oct;16(5):542-3.

Chien CP, Roach M 3rd. Who, when, where, and how: salvage prostate cancer with radiotherapy. Oncology (Williston Park). 2010 Jul;24(8):702, 704.

Hamstra DA, Michalski JM, Roach M, Sandler HM. Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol. 2010 Oct 1;28(28):e518-9; author reply e521-e522.

Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):445-52. Epub 2010 Aug 24.

Westphalen AC, Coakley FV, Roach M 3rd, McCulloch CE, Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010 Aug;256(2):485-92.

Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1314-22. Epub 2010 Apr 8.

Roach M. Prostate cancer: worse sexual function after cryoablation--a case for EBRT? Nat Rev Urol. 2010 Mar;7(3):122-4.

Roach M 3rd, Nam J, Gagliardi G, El Naqa I, Deasy JO, Marks LB. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S130-4.

Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb;8(2):162-200.

Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M 3rd, Ma L. Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):58-63.

Roach M 3rd. Editorial comment. J Urol. 2010 Feb;183(2):551.

Roach M 3rd. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era: change you can believe in, or back to the future? (In regard to Nguyen PL, et al. (Int J Radiat Oncol Biol Phys 2009). Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):316.

Chow E, James J, Barsevick A, Hartsell W, Ratcliffe S, Scarantino C, Ivker R, Roach M, Suh J, Petersen I, Konski A, Demas W, Bruner D. Functional interference clusters in cancer patients with bone metastases: a secondary analysis of RTOG 9714. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1507-11.

Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):14-22.

Konski A, James J, Hartsell W, Leibenhaut MH, Janjan N, Curran W, Roach M, Watkins-Bruner D.Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am J Clin Oncol. 2009 Aug;32(4):423-8.

Roach M 3rd, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer. 2009 Jul 1;115(13 Suppl):3112-20.

Potters L, Roach M 3rd, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1061-5.

Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy. 2009 Oct-Dec;8(4):339-44.

Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M 3rd. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):36-42.

Michalski JM, Roach M 3rd, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):667-72.

Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M 3rd, Shinohara K. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int. 2009 Sep;104(5):600-4.

Roach M 3rd. Predicting pathologic stage, nomograms, and clinical judgment: don't miss the forest for the trees! Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):325-6.

Schröder FH, Roach M 3rd, Scardino P. Clinical decisions. Management of prostate cancer. N Engl J Med. 2008 Dec 11;359(24):2605-9.

Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M 3rd, Pisansky TM, Seider M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):377-82.

Joseph T, McKenna DA, Westphalen AC, Coakley FV, Zhao S, Lu Y, Hsu IC, Roach M 3rd, Kurhanewicz J. Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):665-71. Epub 2008 Aug 28.

Sahgal A, Jabbari S, Chen J, Pickett B, Roach M 3rd, Weinberg V, Hsu IC, Pouliot J. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):247-54.

Roach M 3rd. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol. 2008 Aug 1;26(22):3816-7; author reply 3817-8.

Yu JS, Roach M 3rd. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 Jul 10;359(2):200; author reply 201-2.

Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):341-6.

Hartsell WF, Desilvio M, Bruner DW, Scarantino C, Ivker R, Roach M 3rd, Suh J, Demas WF, Movsas B, Petersen IA, Konski AA. Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14. J Palliat Med. 2008 Jun;11(5):723-8.

Roach M 3rd. "Short- and long-term mortality with localized prostate cancer": errors and omissions? Arch Intern Med. 2008 Jun 23;168(12):1351.

Taussky D, Bae K, Bahary JP, Roach M 3rd, Lawton CA, Shipley WU, Sandler HM. Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. Urology. 2008 Nov;72(5):1125-9.

Chan LW, Xia P, Gottschalk AR, et al. and Roach, M., 3^rd,  Proposed Rectal Dose Constraints for Patients Undergoing Definitive Whole Pelvic Radiotherapy for Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. Mar 12 2008.

Chung HT, Xia P, Chan LW, Park-Somers E, and Roach, M., 3^rd, Does Image-Guided Radiotherapy Improve Toxicity Profile in Whole Pelvic-Treated High-Risk Prostate Cancer? Comparison Between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. May 21 2008. 

Shinohara K, Roach, M., 3^rd, Technique for implantation of fiducial markers in the prostate. Urology. Feb 2008;71(2):196-200. 

Roach, M., 3^rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. Feb 1 2008;26(4):585-591. 

D'ambrosio DJ, Pollack A, Harris EER, Price RA, Verhey LJ, Roach, M., 3^rd, Demanes DJ, Steinberg ML, Potters L, Wallern PE, Konski A.  Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.  Int J Radiation Oncol Biol Phys.  70 (3):671-77, 2008.

McKenna DA, Coakley FV, Westphalen AC, et al. Prostate Cancer: Role of Pretreatment MR in Predicting Outcome after External-Beam Radiation Therapy-Initial Experience. Radiology. Feb 7 2008.

Lometti MW, Thurston D, Aubin M, …and Roach, M., 3^rd, Are lateral electronic portal images adequate for accurate on-line daily targeting of the prostate? Results of a prospective study. Med Dosim. Spring 2008;33(1):22-29.

Schiffner DC, Gottschalk AR, Lometti M, et al. and Roach, M., 3^rd, Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. Feb 1 2007;67(2):610-619.

Sahgal A, Roach, M., 3^rd, Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application. Nat Clin Pract Urol. Dec 2007;4(12):658-670.

Roach, M., 3^rd, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer. Jan 15 2007;109(2):213-220. 

Roach, M., 3^rd, De Silvio M, Rebbick T, et al. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys. Sep 1 2007;69(1):79-87. 

Frank SJ, Grimm PD, Sylvester JE, et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. Jan-Mar 2007;6(1):2-8.

Zapotoczna A, Sasso G, Simpson J, Roach, M., 3^rd, Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia. Jun 2007;9(6):455-463. 

Lawton CA, DeSilvio M, Roach, M., 3^rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.  Int J Radiation Oncol Biol Phys. 69(3):464-55, 2007. 

Ludlum E, Mu G, Weinberg V, Roach M, 3rd, Verhey LJ, Xia P. An algorithm for shifting MLC shapes to adjust for daily prostate movement during concurrent treatment with pelvic lymph nodes. Med Phys. Dec 2007;34(12):4750-4756.

Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. Dec 1 2007;69(5):1472-1477.

Litzenberg DW, Willoughby TR, Balter JM, et al. Positional Stability of Electromagnetic Transponders Used for Prostate Localization and Continuous, Real-Time Tracking. Int J Radiat Oncol Biol Phys. May 18 2007.

Speight JL, Roach, M., 3^rd, Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol. Mar 10 2007;25(8):987-995. 

Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. Mar 15 2007;67(4):1106-1112. 

More Publications